Pemphigus Vulgaris - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Pemphigus Vulgaris Emerging Therapy and TPP Insights

Thelansis's "Pemphigus Vulgaris Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Pemphigus Vulgaris Overview

Pemphigus vulgaris is a rare, potentially life-threatening autoimmune blistering disease in which antibodies attack proteins responsible for holding skin cells together, causing painful blistering and erosion across the skin and mucous membranes that can become extensive without treatment. For most of the modern treatment era, care relied on high-dose corticosteroids paired with various immunosuppressants, an approach that could control the disease but often at the cost of significant long-term side effects. That changed when a B-cell depleting antibody therapy became the first biologic approved for the condition, a genuine milestone after decades without a major treatment advance, and it is now recommended alongside corticosteroids as first-line therapy based on trial evidence showing meaningfully better outcomes than steroids alone. What makes pemphigus somewhat unusual within antibody-mediated autoimmune disease is that this success has been difficult to replicate, with newer mechanisms that succeeded in closely related conditions failing to show similar benefit here, prompting renewed interest in why trial outcomes diverge.

Key Highlights

• In Germany, prevalent Pemphigus Vulgaris (PV) cases are projected to increase from 7,972 in 2025 to 11,793 by 2035.
• Pemphigus Vulgaris is a rare autoimmune blistering disease causing painful skin and mucosal lesions.
• Despite available immunosuppressive therapies, disease relapse and treatment-related adverse effects remain major challenges.
• Significant unmet need remains for targeted therapies that provide durable disease control.

Market Overview

• The Spain Pemphigus Vulgaris market is projected to grow from $12M in 2025 to $26M by 2035.
• Market growth is driven by:
• Increasing adoption of biologic and targeted immunotherapies
• Improved diagnosis and disease management
• Future growth will depend on therapies offering sustained remission with improved safety profiles.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Cabaletta Bio